---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-037111"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T20:03:19.040296+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# APAC to merge with Ligand's OmniAb antibody discovery business at $850M valuation

## Summary
- Pre-money equity valuation of $850M; minimum $130M gross cash to combined company, up to $266M.
- Avista commits up to $115M ($15M PIPE + $100M backstop); Ligand contributes $15M.
- Ligand shareholders to own 75-84% of combined firm; APAC shareholders ~20%, Avista ~5%.
- Transaction expected to close H2 2022; OmniAb to list on Nasdaq as 'OABI'.
- Matt Foehr named CEO of OmniAb; Kurt Gustafson appointed CFO.

## SEC filing metadata
- accession: 0001104659-22-037111
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000110465922037111/0001104659-22-037111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000110465922037111/tm2210239d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-037111
- JSON: https://secwatch.observer/filing/0001104659-22-037111.json
- Plain text: https://secwatch.observer/filing/0001104659-22-037111.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.